Full Professor

The petition was approved based on meeting at least three EB-1A criteria: authorship of scholarly articles, participation as a judge of others' work, and original scientific contributions of major significance. Specific metrics included 34 journal articles in high-impact venues like Cell Chemical Biology, 1,306 citations with an h-index of 17, and over 25 completed manuscript reviews. Evidence of the commercialization of key compounds further demonstrated the petitioner's extraordinary ability.

The approval was based on a significant publication record of 28 journal articles and a citation count exceeding 360, placing the petitioner in the top 1% of his field. Additionally, his 25 peer reviews and original contributions to antimicrobial and antidiabetic agents satisfied the EB-1A criteria.

The petition was approved based on a scholarly portfolio of 15 peer-reviewed publications in top-tier journals like Nature Methods and PNAS, which garnered 254 citations. The petitioner demonstrated professional standing through over 18 peer reviews for high-impact journals and service on editorial boards. Additionally, the research attracted funding from prestigious bodies including the NIH, NSF, and National Cancer Institute.

The petition was approved based on the documentation of 24 peer-reviewed journal articles and a high citation count of 596, placing the applicant in the top 3% of her field. Additionally, her participation in at least 10 journal reviews satisfied the judging criterion. The case was further strengthened by evidence of support from the Department of Energy (DOE) and expert testimony regarding her impact on pharmaceutical development.